8-K 1 ritrievi8-k.htm 8-K - RITRIEVI DIRECTOR Document

Washington, D.C. 20549

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
March 6. 2018
Date of Report (Date of earliest event reported)


(Exact name of registrant as specified in its charter)

(State or other jurisdiction of incorporation)
(I.R.S. Employer Identification No.)
100 North Point Center East, Suite 600
Alpharetta, Georgia
(Address of principal executive offices)
(Zip code)
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o  Written communications pursuant to Rule 425 under the Securities Act. (17 CFR 230.425)
o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act. (17 CFR 240.14a-12)
o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. (17 CFR 240.14d-2(b))
o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. (17 CFR 240.13e-4(c))

o  Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
o  If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Election of Directors
On March 1, 2018, the Board of Directors of Schweitzer-Mauduit International, Inc. appointed Dr. Kimberly E. Ritrievi as a director and member of the Audit and Compensation Committees, all effective as of March 1, 2018.

As compensation for her service on the Board, Dr. Ritrievi will receive the Company’s standard compensation for non-employee directors. Dr. Ritrievi has no family relationships with any director or executive officer of the Company, and there were no arrangements or understandings with any person pursuant to which she was selected as a director of the Company. In addition, there have been no transactions directly or indirectly involving Dr. Ritrievi that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Schweitzer-Mauduit International, Inc.

By:/s/ Ricardo Nuñez    
Ricardo Nuñez
General Counsel and
Corporate Secretary

Dated: March 6, 2018